New preclinical guidelines on drug effects on ventricular repolarization: Safety pharmacology comes of age
Authors:
- Lewis B KinterLKLewis B Kinter
- Peter K.S SieglPSPeter K.S Siegl
- Alan S BassABAlan S Bass
- 1 May 2004
- journal article
- review article
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 49 (3) , 153-158
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug developmentCardiovascular Research, 2003
- Cardiac repolarization: Current knowledge, critical gaps, and new approaches to drug development and patient managementAmerican Heart Journal, 2002
- Safety pharmacology and risk assessmentFundamental & Clinical Pharmacology, 2002
- Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensusEuropean Journal of Clinical Pharmacology, 2001
- Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international surveyCardiovascular Research, 2001
- Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology & Therapeutics, 2001
- The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: Clinical and regulatory implications Report on a Policy Conference of the European Society of CardiologyCardiovascular Research, 2000
- The QT Interval and Torsade de PointesDrug Safety, 1999
- The Heart Rate-Corrected QT Interval of Conscious Beagle Dogs: A Formula Based on Analysis of CovarianceToxicological Sciences, 1998
- The Long QT Syndrome: Ion Channel Diseases of the HeartMayo Clinic Proceedings, 1998